Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Cigarette Smoking as a Predictor of Sodium-Glucose Cotransporter 2 Inhibitor-Associated Genital Infections: A Retrospective Cohort Study.

Diabetes care

Scoccimarro D, Cipani G, Dicembrini I, Mannucci E.
PMID: 33883197
Diabetes Care. 2021 Jun;44(6):e127-e128. doi: 10.2337/dc21-0308. Epub 2021 Apr 21.

No abstract available.

Cite
Scoccimarro D, Cipani G, Dicembrini I, et al. Cigarette Smoking as a Predictor of Sodium-Glucose Cotransporter 2 Inhibitor-Associated Genital Infections: A Retrospective Cohort Study. Diabetes Care. 2021;44(6):e127-e128doi: 10.2337/dc21-0308.
Scoccimarro, D., Cipani, G., Dicembrini, I., & Mannucci, E. (2021). Cigarette Smoking as a Predictor of Sodium-Glucose Cotransporter 2 Inhibitor-Associated Genital Infections: A Retrospective Cohort Study. Diabetes care, 44(6), e127-e128. https://doi.org/10.2337/dc21-0308
Scoccimarro, Daniele, et al. "Cigarette Smoking as a Predictor of Sodium-Glucose Cotransporter 2 Inhibitor-Associated Genital Infections: A Retrospective Cohort Study." Diabetes care vol. 44,6 (2021): e127-e128. doi: https://doi.org/10.2337/dc21-0308
Scoccimarro D, Cipani G, Dicembrini I, Mannucci E. Cigarette Smoking as a Predictor of Sodium-Glucose Cotransporter 2 Inhibitor-Associated Genital Infections: A Retrospective Cohort Study. Diabetes Care. 2021 Jun;44(6):e127-e128. doi: 10.2337/dc21-0308. Epub 2021 Apr 21. PMID: 33883197; PMCID: PMC8247508.
Copy Download .nbib Format: NLM
Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

Neuen BL, Cherney DZ, Jardine MJ, Perkovic V.
PMID: 31615819
CMAJ. 2019 Oct 15;191(41):E1128-E1135. doi: 10.1503/cmaj.190047.

No abstract available.

Cite
Neuen BL, Cherney DZ, Jardine MJ, et al. Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. CMAJ. 2019;191(41):E1128-E1135doi: 10.1503/cmaj.190047.
Neuen, B. L., Cherney, D. Z., Jardine, M. J., & Perkovic, V. (2019). Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 191(41), E1128-E1135. https://doi.org/10.1503/cmaj.190047
Neuen, Brendon L, et al. "Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering." CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne vol. 191,41 (2019): E1128-E1135. doi: https://doi.org/10.1503/cmaj.190047
Neuen BL, Cherney DZ, Jardine MJ, Perkovic V. Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. CMAJ. 2019 Oct 15;191(41):E1128-E1135. doi: 10.1503/cmaj.190047. PMID: 31615819; PMCID: PMC6791785.
Copy Download .nbib Format: NLM
VERTIS-CV: More Evidence That Sodium Glucose Cotransporter 2 Inhibition Brings Rapid and Sustained Heart Failure Benefit.

Circulation

Zannad F, Cowie MR.
PMID: 33284652
Circulation. 2020 Dec 08;142(23):2216-2218. doi: 10.1161/CIRCULATIONAHA.120.050512. Epub 2020 Dec 07.

No abstract available.

Cite
Zannad F, Cowie MR. VERTIS-CV: More Evidence That Sodium Glucose Cotransporter 2 Inhibition Brings Rapid and Sustained Heart Failure Benefit. Circulation. 2020;142(23):2216-2218doi: 10.1161/CIRCULATIONAHA.120.050512.
Zannad, F., & Cowie, M. R. (2020). VERTIS-CV: More Evidence That Sodium Glucose Cotransporter 2 Inhibition Brings Rapid and Sustained Heart Failure Benefit. Circulation, 142(23), 2216-2218. https://doi.org/10.1161/CIRCULATIONAHA.120.050512
Zannad, Faiez, and Cowie, Martin R. "VERTIS-CV: More Evidence That Sodium Glucose Cotransporter 2 Inhibition Brings Rapid and Sustained Heart Failure Benefit." Circulation vol. 142,23 (2020): 2216-2218. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.050512
Zannad F, Cowie MR. VERTIS-CV: More Evidence That Sodium Glucose Cotransporter 2 Inhibition Brings Rapid and Sustained Heart Failure Benefit. Circulation. 2020 Dec 08;142(23):2216-2218. doi: 10.1161/CIRCULATIONAHA.120.050512. Epub 2020 Dec 07. PMID: 33284652.
Copy Download .nbib Format: NLM
SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.

Frontiers in public health

Shi N, Shi Y, Xu J, Si Y, Yang T, Zhang M, Ng DM, Li X, Xie F.
PMID: 34164370
Front Public Health. 2021 Jun 07;9:668368. doi: 10.3389/fpubh.2021.668368. eCollection 2021.

No abstract available.

Cite
Shi N, Shi Y, Xu J, et al. SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Front Public Health. 2021;9:668368doi: 10.3389/fpubh.2021.668368.
Shi, N., Shi, Y., Xu, J., Si, Y., Yang, T., Zhang, M., Ng, D. M., Li, X., & Xie, F. (2021). SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Frontiers in public health, 9668368. https://doi.org/10.3389/fpubh.2021.668368
Shi, Nanjing, et al. "SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials." Frontiers in public health vol. 9 (2021): 668368. doi: https://doi.org/10.3389/fpubh.2021.668368
Shi N, Shi Y, Xu J, Si Y, Yang T, Zhang M, Ng DM, Li X, Xie F. SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Front Public Health. 2021 Jun 07;9:668368. doi: 10.3389/fpubh.2021.668368. eCollection 2021. PMID: 34164370; PMCID: PMC8215266.
Copy Download .nbib Format: NLM
Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States.

Diabetes, obesity & metabolism

Dawwas GK, Leonard CE, Garg M, Vouri SM, Smith SM, Flory JH, Genuardi MV, Park H.
PMID: 31903713
Diabetes Obes Metab. 2020 Apr;22(4):705-710. doi: 10.1111/dom.13949. Epub 2020 Jan 19.

We conducted a cross-sectional analysis using a database from commercial health plans in the United States to describe trends in the use of antidiabetic medications among patients with type 2 diabetes and heart failure (HF) from 2006 through 2017....

Cite
Dawwas GK, Leonard CE, Garg M, et al. Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. Diabetes Obes Metab. 2020;22(4):705-710doi: 10.1111/dom.13949.
Dawwas, G. K., Leonard, C. E., Garg, M., Vouri, S. M., Smith, S. M., Flory, J. H., Genuardi, M. V., & Park, H. (2020). Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. Diabetes, obesity & metabolism, 22(4), 705-710. https://doi.org/10.1111/dom.13949
Dawwas, Ghadeer K, et al. "Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States." Diabetes, obesity & metabolism vol. 22,4 (2020): 705-710. doi: https://doi.org/10.1111/dom.13949
Dawwas GK, Leonard CE, Garg M, Vouri SM, Smith SM, Flory JH, Genuardi MV, Park H. Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. Diabetes Obes Metab. 2020 Apr;22(4):705-710. doi: 10.1111/dom.13949. Epub 2020 Jan 19. PMID: 31903713.
Copy Download .nbib Format: NLM
SGLT2 Inhibitors in Liver Patients.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Hsiang JC, Wong VW.
PMID: 32428710
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2168-2172.e2. doi: 10.1016/j.cgh.2020.05.021. Epub 2020 May 16.

No abstract available.

Cite
Hsiang JC, Wong VW. SGLT2 Inhibitors in Liver Patients. Clin Gastroenterol Hepatol. 2020;18(10):2168-2172.e2doi: 10.1016/j.cgh.2020.05.021.
Hsiang, J. C., & Wong, V. W. (2020). SGLT2 Inhibitors in Liver Patients. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 18(10), 2168-2172.e2. https://doi.org/10.1016/j.cgh.2020.05.021
Hsiang, John Chen, and Wong, Vincent Wai-Sun. "SGLT2 Inhibitors in Liver Patients." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. 18,10 (2020): 2168-2172.e2. doi: https://doi.org/10.1016/j.cgh.2020.05.021
Hsiang JC, Wong VW. SGLT2 Inhibitors in Liver Patients. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2168-2172.e2. doi: 10.1016/j.cgh.2020.05.021. Epub 2020 May 16. PMID: 32428710.
Copy Download .nbib Format: NLM
Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus.

Current drug safety

Singh M, Sharma R, Kumar A.
PMID: 30727912
Curr Drug Saf. 2019;14(2):87-93. doi: 10.2174/1574886314666190206164647.

BACKGROUND: Recently, Food and Drug Administration (FDA) has approved sodium/ glucose co-transporter 2 (SGLT2) inhibitors for the treatment of diabetes mellitus. However, regarding adverse drug reactions (ADRs) of SGLT2 inhibitors in large group of population, very less information is...

Cite
Singh M, Sharma R, Kumar A. Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Curr Drug Saf. 2019;14(2):87-93doi: 10.2174/1574886314666190206164647.
Singh, M., Sharma, R., & Kumar, A. (2019). Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Current drug safety, 14(2), 87-93. https://doi.org/10.2174/1574886314666190206164647
Singh, Mahakpreet, et al. "Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus." Current drug safety vol. 14,2 (2019): 87-93. doi: https://doi.org/10.2174/1574886314666190206164647
Singh M, Sharma R, Kumar A. Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Curr Drug Saf. 2019;14(2):87-93. doi: 10.2174/1574886314666190206164647. PMID: 30727912.
Copy Download .nbib Format: NLM
Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications.

Current cardiology reports

Bassi N, Fonarow GC.
PMID: 30259198
Curr Cardiol Rep. 2018 Sep 26;20(11):112. doi: 10.1007/s11886-018-1050-3.

PURPOSE OF REVIEW: Type 2 diabetes mellitus (DM) is a major risk factor for the development of heart failure (HF). In patients with DM, preventing HF using diabetes medications should be an imperative for primary care physicians and cardiologists...

Cite
Bassi N, Fonarow GC. Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications. Curr Cardiol Rep. 2018;20(11):112doi: 10.1007/s11886-018-1050-3.
Bassi, N., & Fonarow, G. C. (2018). Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications. Current cardiology reports, 20(11), 112. https://doi.org/10.1007/s11886-018-1050-3
Bassi, Nikhil, and Fonarow, Gregg C. "Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications." Current cardiology reports vol. 20,11 (2018): 112. doi: https://doi.org/10.1007/s11886-018-1050-3
Bassi N, Fonarow GC. Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications. Curr Cardiol Rep. 2018 Sep 26;20(11):112. doi: 10.1007/s11886-018-1050-3. PMID: 30259198.
Copy Download .nbib Format: NLM
Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors.

International journal of molecular sciences

Dąbrowski M.
PMID: 33562380
Int J Mol Sci. 2021 Feb 07;22(4). doi: 10.3390/ijms22041680.

In the last decade, cancer became the leading cause of death in the population under 65 in the European Union. Diabetes is also considered as a factor increasing risk of cancer incidence and mortality. Type 2 diabetes is frequently...

Cite
Dąbrowski M. Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors. Int J Mol Sci. 2021;22(4)doi: 10.3390/ijms22041680.
Dąbrowski, M. (2021). Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors. International journal of molecular sciences, 22(4), . https://doi.org/10.3390/ijms22041680
Dąbrowski, Mariusz. "Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors." International journal of molecular sciences vol. 22,4 (2021). doi: https://doi.org/10.3390/ijms22041680
Dąbrowski M. Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors. Int J Mol Sci. 2021 Feb 07;22(4). doi: 10.3390/ijms22041680. PMID: 33562380; PMCID: PMC7915237.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries